Tianjin Medical Journal ›› 2024, Vol. 52 ›› Issue (9): 900-906.doi: 10.11958/20231828
• Cell and Molecular Biology • Previous Articles Next Articles
LIANG Damin(), YANG Zhengjiu, ZHANG Ziping, QIAN Jing, MAO Chaokun
Received:
2023-12-22
Revised:
2024-04-18
Published:
2024-09-15
Online:
2024-09-06
LIANG Damin, YANG Zhengjiu, ZHANG Ziping, QIAN Jing, MAO Chaokun. Study on the effect and mechanism of kaempferol in reversing drug-resistant Bel-7402/5-Fu cells[J]. Tianjin Medical Journal, 2024, 52(9): 900-906.
CLC Number:
干扰序列 | 序列(5'→3') |
---|---|
siRNA-2142 | 正义:GCAAAGAGGUGGCAGUUAATT |
反义:UUAACUGCCACCUCUUUGCTT | |
siRNA-3785 | 正义:GAACAUGGCAGGAGAGAAUTT |
反义:AUUCUCUCCUGCCAUGUUCTT | |
siRNA-1664 | 正义:GUGAAUUCCUCCAGUGAAATT |
反义:UUUCACUGGAGGAAUUCACTT | |
si-NC | 正义:UUCUCCGAACGUGUCACGUTT |
反义:ACGUGACACGUUCGGAGAATT |
Tab.1 Interference sequence
干扰序列 | 序列(5'→3') |
---|---|
siRNA-2142 | 正义:GCAAAGAGGUGGCAGUUAATT |
反义:UUAACUGCCACCUCUUUGCTT | |
siRNA-3785 | 正义:GAACAUGGCAGGAGAGAAUTT |
反义:AUUCUCUCCUGCCAUGUUCTT | |
siRNA-1664 | 正义:GUGAAUUCCUCCAGUGAAATT |
反义:UUUCACUGGAGGAAUUCACTT | |
si-NC | 正义:UUCUCCGAACGUGUCACGUTT |
反义:ACGUGACACGUUCGGAGAATT |
基因名称 | 引物序列(5'→3') | 产物大小/bp |
---|---|---|
DNA-PKcs | 上游:CCTGGCCGGTCATCAACTG | 227 |
下游:AGTAAGGTGCGATCTTCTGGC | ||
γ-H2AX | 上游:CTACTCCGAACGAGTCGGG | 125 |
下游:GATGGTCACGCGACCTAGAAG | ||
Artemis | 上游:TATGCCGGTCTTCCCAAAGTA | 164 |
下游:GTGAAAAGTTTCCGGGTATGGA | ||
P-gp | 上游:GCACAGGAGAATTGATTAACCGC | 118 |
下游:ATACTGATGCCTACGGAAGCC | ||
GAPDH | 上游:TGTGGGCATCAATGGATTTGG | 116 |
下游:ACACCATGTATTCCGGGTCAAT |
Tab.2 Primer sequence
基因名称 | 引物序列(5'→3') | 产物大小/bp |
---|---|---|
DNA-PKcs | 上游:CCTGGCCGGTCATCAACTG | 227 |
下游:AGTAAGGTGCGATCTTCTGGC | ||
γ-H2AX | 上游:CTACTCCGAACGAGTCGGG | 125 |
下游:GATGGTCACGCGACCTAGAAG | ||
Artemis | 上游:TATGCCGGTCTTCCCAAAGTA | 164 |
下游:GTGAAAAGTTTCCGGGTATGGA | ||
P-gp | 上游:GCACAGGAGAATTGATTAACCGC | 118 |
下游:ATACTGATGCCTACGGAAGCC | ||
GAPDH | 上游:TGTGGGCATCAATGGATTTGG | 116 |
下游:ACACCATGTATTCCGGGTCAAT |
组别 | 0 h | 24 h | 48 h | 72 h | F |
---|---|---|---|---|---|
对照组 | 100.00±0.00 | 114.67±9.87 | 121.33±13.50 | 127.00±15.88 | 3.062 |
0.064 μmol/L组 | 102.00±1.00 | 107.33±11.02 | 115.67±9.61 | 116.67±10.63 | 1.175 |
0.320 μmol/L组 | 100.62±1.07 | 105.33±9.51 | 113.67±12.01 | 119.33±11.28 | 1.469 |
1.600 μmol/L组 | 98.50±1.80 | 103.00±7.55 | 112.67±8.62 | 116.86±16.01 | 2.107 |
8 μmol/L组 | 100.83±1.76 | 53.00±8.19aA | 41.00±6.56aA | 34.66±2.52aA | 90.160* |
40 μmol/L组 | 99.80±1.26 | 40.65±7.50aA | 36.66±7.64aA | 29.67±3.22aA | 99.540* |
200 μmol/L组 | 100.53±0.92 | 42.33±8.74aA | 31.33±6.51aA | 20.00±4.03aA | 113.700* |
F | 2.750 | 42.130* | 60.040* | 45.020* |
Tab.3 Comparison of survival rate between seven groups of Bel-7402/5-Fu cells
组别 | 0 h | 24 h | 48 h | 72 h | F |
---|---|---|---|---|---|
对照组 | 100.00±0.00 | 114.67±9.87 | 121.33±13.50 | 127.00±15.88 | 3.062 |
0.064 μmol/L组 | 102.00±1.00 | 107.33±11.02 | 115.67±9.61 | 116.67±10.63 | 1.175 |
0.320 μmol/L组 | 100.62±1.07 | 105.33±9.51 | 113.67±12.01 | 119.33±11.28 | 1.469 |
1.600 μmol/L组 | 98.50±1.80 | 103.00±7.55 | 112.67±8.62 | 116.86±16.01 | 2.107 |
8 μmol/L组 | 100.83±1.76 | 53.00±8.19aA | 41.00±6.56aA | 34.66±2.52aA | 90.160* |
40 μmol/L组 | 99.80±1.26 | 40.65±7.50aA | 36.66±7.64aA | 29.67±3.22aA | 99.540* |
200 μmol/L组 | 100.53±0.92 | 42.33±8.74aA | 31.33±6.51aA | 20.00±4.03aA | 113.700* |
F | 2.750 | 42.130* | 60.040* | 45.020* |
组别 | γ-H2AX | DNA-PKcs | Artemis | P-gp | ||||
---|---|---|---|---|---|---|---|---|
mRNA | 蛋白 | mRNA | 蛋白 | mRNA | 蛋白 | mRNA | 蛋白 | |
对照组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
KAE组 | 1.75±0.08 | 3.23±0.15 | 0.55±0.08 | 0.47±0.04 | 0.71±0.04 | 0.44±0.03 | 0.38±0.05 | 0.21±0.03 |
t | 16.490* | 25.320* | 10.580* | 25.980* | 23.690* | 38.770* | 11.010* | 45.170* |
Tab.4 Comparison of γ-H2AX, DNA-PKcs, Artemis and P-gp mRNA and protein expressions between two groups of cells
组别 | γ-H2AX | DNA-PKcs | Artemis | P-gp | ||||
---|---|---|---|---|---|---|---|---|
mRNA | 蛋白 | mRNA | 蛋白 | mRNA | 蛋白 | mRNA | 蛋白 | |
对照组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
KAE组 | 1.75±0.08 | 3.23±0.15 | 0.55±0.08 | 0.47±0.04 | 0.71±0.04 | 0.44±0.03 | 0.38±0.05 | 0.21±0.03 |
t | 16.490* | 25.320* | 10.580* | 25.980* | 23.690* | 38.770* | 11.010* | 45.170* |
组别 | 细胞凋亡率 | 细胞周期 | ||
---|---|---|---|---|
G0/G1 | S | G2/M | ||
对照组 | 3.16±0.31 | 47.34±0.94 | 19.53±2.91 | 33.12±2.03 |
KAE组 | 17.81±0.02 | 41.34±1.07 | 19.90±0.95 | 38.72±1.21 |
t | 83.080* | 7.250* | 0.209 | 4.100* |
Tab.5 The effect of KAE on cell cycle and apoptosis
组别 | 细胞凋亡率 | 细胞周期 | ||
---|---|---|---|---|
G0/G1 | S | G2/M | ||
对照组 | 3.16±0.31 | 47.34±0.94 | 19.53±2.91 | 33.12±2.03 |
KAE组 | 17.81±0.02 | 41.34±1.07 | 19.90±0.95 | 38.72±1.21 |
t | 83.080* | 7.250* | 0.209 | 4.100* |
组别 | DNA-PKcs | |
---|---|---|
mRNA | 蛋白 | |
si-NC组 | 1.00±0.00 | 1.00±0.00 |
siRNA-1664组 | 0.30±0.01a | 0.36±0.04a |
siRNA-2142组 | 0.40±0.02ab | 0.53±0.09ab |
siRNA-3785组 | 0.48±0.02abc | 0.37±0.03ac |
F | 1 361.000* | 94.040* |
Tab.6 Comparison of DNA-PKcs mRNA and protein expression levels between four groups of cells
组别 | DNA-PKcs | |
---|---|---|
mRNA | 蛋白 | |
si-NC组 | 1.00±0.00 | 1.00±0.00 |
siRNA-1664组 | 0.30±0.01a | 0.36±0.04a |
siRNA-2142组 | 0.40±0.02ab | 0.53±0.09ab |
siRNA-3785组 | 0.48±0.02abc | 0.37±0.03ac |
F | 1 361.000* | 94.040* |
组别 | 细胞 凋亡率 | 细胞周期 | ||
---|---|---|---|---|
G0/G1 | S | G2/M | ||
si-NC组 | 3.07±0.40 | 49.94±0.89 | 7.67±2.76 | 42.39±1.93 |
DNA-PKcs干扰组 | 21.64±1.35 | 49.21±0.22 | 12.84±0.95 | 37.95±0.91 |
t | 22.840* | 1.380 | 3.065* | 3.605* |
Tab.7 Comparison of cell apoptosis rates and cell cycle distribution between two groups
组别 | 细胞 凋亡率 | 细胞周期 | ||
---|---|---|---|---|
G0/G1 | S | G2/M | ||
si-NC组 | 3.07±0.40 | 49.94±0.89 | 7.67±2.76 | 42.39±1.93 |
DNA-PKcs干扰组 | 21.64±1.35 | 49.21±0.22 | 12.84±0.95 | 37.95±0.91 |
t | 22.840* | 1.380 | 3.065* | 3.605* |
组别 | γ-H2AX | DNA-PKcs | ||
---|---|---|---|---|
mRNA | 蛋白 | mRNA | 蛋白 | |
对照组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
KAE组 | 1.23±0.05a | 1.36±0.05a | 0.60±0.08a | 0.43±0.03a |
KAE+siDNA-PKcs组 | 1.60±0.04ab | 1.94±0.15ab | 0.28±0.08ab | 0.28±0.03ab |
F | 115.900* | 80.810* | 25.530* | 713.100* |
组别 | Artemis | P-gp | ||
mRNA | 蛋白 | mRNA | 蛋白 | |
对照组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
KAE组 | 0.48±0.06a | 0.25±0.04a | 0.70±0.03a | 0.34±0.02a |
KAE+siDNA-PKcs组 | 0.39±0.04ab | 0.16±0.02ab | 0.57±0.04ab | 0.28±0.01ab |
F | 113.500* | 1 147.000* | 134.200* | 871.700* |
Tab.8 Comparison of γ-H2AX, DNA-PKcs, Artemis and P-gp mRNA and protein expressions between three groups of cells
组别 | γ-H2AX | DNA-PKcs | ||
---|---|---|---|---|
mRNA | 蛋白 | mRNA | 蛋白 | |
对照组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
KAE组 | 1.23±0.05a | 1.36±0.05a | 0.60±0.08a | 0.43±0.03a |
KAE+siDNA-PKcs组 | 1.60±0.04ab | 1.94±0.15ab | 0.28±0.08ab | 0.28±0.03ab |
F | 115.900* | 80.810* | 25.530* | 713.100* |
组别 | Artemis | P-gp | ||
mRNA | 蛋白 | mRNA | 蛋白 | |
对照组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
KAE组 | 0.48±0.06a | 0.25±0.04a | 0.70±0.03a | 0.34±0.02a |
KAE+siDNA-PKcs组 | 0.39±0.04ab | 0.16±0.02ab | 0.57±0.04ab | 0.28±0.01ab |
F | 113.500* | 1 147.000* | 134.200* | 871.700* |
组别 | 0 h | 2 h | 4 h |
---|---|---|---|
对照组 | 1.00±0.00 | 0.89±0.04 | 0.84±0.06 |
KAE组 | 1.00±0.00 | 0.36±0.03 | 0.21±0.03 |
t | - | 21.510* | 17.330* |
Tab.9 Comparison of DNA-PKcs protein expressions between two groups of cells
组别 | 0 h | 2 h | 4 h |
---|---|---|---|
对照组 | 1.00±0.00 | 0.89±0.04 | 0.84±0.06 |
KAE组 | 1.00±0.00 | 0.36±0.03 | 0.21±0.03 |
t | - | 21.510* | 17.330* |
组别 | DNA-PKcs蛋白 | Ub蛋白 |
---|---|---|
对照组 | 1.00±0.00 | 1.00±0.00 |
KAE+DMSO组 | 0.27±0.05a | 1.32±0.11a |
KAE+CQ组 | 0.31±0.04a | - |
KAE+MG132组 | 0.64±0.07abc | 0.79±0.06ab |
F | 178.500* | 44.200* |
Tab.10 Expression of DNA-PKcs and their Ub in cells of each treatment group
组别 | DNA-PKcs蛋白 | Ub蛋白 |
---|---|---|
对照组 | 1.00±0.00 | 1.00±0.00 |
KAE+DMSO组 | 0.27±0.05a | 1.32±0.11a |
KAE+CQ组 | 0.31±0.04a | - |
KAE+MG132组 | 0.64±0.07abc | 0.79±0.06ab |
F | 178.500* | 44.200* |
[1] | TANG Z, HE J, ZOU J, et al. Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC[J]. PeerJ, 2021, 13(9):e11200. doi:10.7717/peerj.11200. |
[2] | LEE K H. Primary cilia:a novel research approach to overcome anticancer drug resistance[J]. Front Mol Biosci, 2023, 2(10):1270639. doi:10.3389/fmolb.2023.1270639. |
[3] | KRENNING L, BERG J, MEDEMA R H. Life or death after a break:what determines the choice?[J]. Mol Cell, 2019, 76(2):346-358. doi:10.1016/j.molcel.2019.08.023. |
[4] | ZHAO Y, THOMAS H D, BATEY M A, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441[J]. Cancer Res, 2006, 66(10):5354-5362. doi:10.1158/0008-5472. |
[5] | FOK J H L, RAMOS M A, VAZQUEZ C M, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation,chemotherapy and olaparib activity[J]. Nat Commun, 2019, 10(1):5065. doi:10.1038/s41467-019-12836-9. |
[6] | CHEN M, XIAO J, SEEDI H R, et al. Kaempferol and atherosclerosis:from mechanism to medicine[J]. Crit Rev Food Sci Nutr, 2024, 64(8):2157-2175. doi:10.1080/10408398.2022.2121261. |
[7] | ZHANG Y, QU Y, CHEN Y Z. Influence of 6-shogaol potentiated on 5-fluorouracil treatment of liver cancer by promoting apoptosis and cell cycle arrest by regulating AKT/mTOR/MRP1 signaling[J]. Chin J Nat Med, 2022, 20(5):352-363. doi:10.1016/S1875-5364(22)60174-2. |
[8] | BABY J, DEVAN A R, KUMAR A R, et al. Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma:a review[J]. J Food Biochem, 2021, 45(7):e13761. doi:10.1111/jfbc.13761. |
[9] | WU H, DU J, LI C, et al. Kaempferol can reverse the 5-Fu resistance of colorectal cancer cells by inhibiting PKM2-mediated glycolysis[J]. Int J Mol Sci, 2022, 23(7):3544. doi:10.3390/ijms23073544. |
[10] | RIAHI C I, SOUID S, OTHMAN H, et al. The Phenolic compound kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells[J]. Sci Rep, 2019, 9(1):195. doi:10.1038/s41598-018-36808-z. |
[11] | DING J, LI X, KHAN S, et al. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs:a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma[J]. Neuro Oncol, 2022, 24(10):1712-1725. doi:10.1093/neuonc/noac105. |
[12] | SHABKHIZAN R, HAIATV S, MOSLEHIAN M S, et al. The beneficial and adverse effects of autophagic response to caloric restriction and fasting[J]. Adv Nutr, 2023, 14(5):1211-1225. doi:10.1016/j.advnut.2023.07.006. |
[13] | KWON Y T, CIECHANOVER A. The ubiquitin code in the ubiquitin-proteasome system and autophagy[J]. Trends Biochem Sci, 2017, 42(11):873-886. doi:10.1016/j.tibs.2017.09.002. |
[14] | FERGUSON B J, MANSUR D S, PETERS N E, et al. DNA-PK is a DNA sensor for IRF-3-dependent innate immunity[J]. Elife, 2012, 1:e00047. doi:10.7554/eLife.00047. |
[15] | HO S R, MAHANIC C S, LEE Y J, et al. RNF144A,an E3 ubiquitin ligase for DNA-PKcs,promotes apoptosis during DNA damage[J]. Proc Natl Acad Sci U S A, 2014, 111(26):E2646-E2655. doi:10.1073/pnas.1323107111. |
[16] | LI Y H, ZHONG M, ZANG H L, et al. MTA1 promotes hepatocellular carcinoma progression by downregulation of DNA-PK-mediated H1.2T146 phosphorylation[J]. Front Oncol, 2020, 10:567. doi:10.3389/fonc.2020.00567. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||